Kiora Pharmaceuticals Secures $5M Equity Financing, Extends Cash Runway to Late 2028
KPRX sits 38% above its 52-week low of $1.765 on light trading volume (0.3× avg).
Summary
Kiora Pharmaceuticals announced a strategic equity financing of $5.0 million, led by Perceptive Advisors, which significantly strengthens its balance sheet and extends its operational cash runway into late 2028. This is a material improvement from the late 2027 runway previously reported in the company's last 10-K. The financing provides crucial capital for the clinical-stage biotech, which also reported active enrollment and site expansion for its Phase 2 ABACUS-2 study of KIO-301, along with the publication of positive ABACUS-1 results in Nature Medicine. Additionally, the company is progressing in its Phase 2 KLARITY study for KIO-104, with an upcoming safety review. The secured funding and extended runway are critical for advancing these programs and reducing near-term financing risk for the micro-cap company.
At the time of this announcement, KPRX was trading at $2.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.7M. The 52-week trading range was $1.76 to $4.18. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: TMX Newsfile.